Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer

Inclusion Criteria: * Women with histologically confirmed epithelial ovarian cancer (stage II / III / IV disease of FIGO) or tumor recurrences (the women of childbearing age need to have a negative pregnancy test) * Complete cytoreduction: Index CC0/CC1 cytoreduction (residual tumor size after surgery, no visible (CC0) or less than 0.25 cm (CC1)) * No extra-abdominal tumor disease * Absence of heart failure. Adequate renal and hepatic functions * Eastern Cooperative Oncology Group performance status 0-2 or Karnofsky performance status ≥ 70% Exclusion Criteria: * Patients with unresectable tumor or incomplete cytoreduction. * Contraindications for treatment with paclitaxel: patients with severe hypersensitivity to paclitaxel or any of the excipients,pregnancy or lactation and patients with baseline neutrophil count \<1.500/mm3 (\<1.000/mm3 for patients with Kaposi sarcoma). Paclitaxel is also contraindicated in patients who have concurrent and severe infections. * Extra-abdominal metastases or unresectable liver metastases * Presence of other malignant tumor disease. * Multisegmental complete bowel obstruction. * Patients with severe medical problems that will preclude compliance with the study or with an unacceptable risk * Patients who refuse treatment or consent to participate in study